Form 4: Vericel Corp CEO Dominick Colangelo Executes Stock Options and Sells Shares Under 10b5-1 Plan

Vericel Corp's CEO, Dominick Colangelo, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Dominick Colangelo, President and CEO of Vericel Corp, executed stock options to acquire 17,500 shares of common stock on both May 15 and May 16, 2024, at an exercise price of $3.02 per share.
• Concurrently, Colangelo sold 17,500 shares on each of those days at prices of $49.67 and $47.85, respectively.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on September 1, 2023.
• Following these transactions, Colangelo directly owns 220,752 shares of Vericel Corp common stock.
• He also holds options to purchase 210,000 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports routine transactions under a pre-existing trading plan. There is no indication of positive or negative implications for the company.

Industry Context

This filing is a routine disclosure of insider transactions. It is common for executives to utilize 10b5-1 plans to diversify their holdings and avoid accusations of trading on inside information. The impact on the stock price is usually minimal unless the transactions are unusually large or frequent.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a form of long-term incentive.
• Rule 10b5-1 trading plans are a standard practice among corporate executives to manage their stock holdings in compliance with insider trading regulations.
• Companies like Amgen, Biogen, and Regeneron also see similar filings from their executives regularly.

Stakeholder Impact

• The transactions are unlikely to have a significant impact on shareholders, employees, customers, suppliers, or creditors.

Key Dates